DYSLIPIDEMIA IN PATIENTS WITH DIABETES: ETIOLOGY AND MANAGEMENT

PDF

Published: 2021-05-31

Page: 118-126


MURIEL DERRIEN *

Department of Pharmacy, University of Reims, Reims, France.

PHILIPPE BOUCHET

Department of Pharmacy, University of Reims, Reims, France.

*Author to whom correspondence should be addressed.


Abstract

Diabetic dyslipidemia is a cluster of lipoprotein abnormalities characterized by increase in triglyceride level, decrease in high-density lipoprotein-cholesterol levels and increase in small dense low-density lipoprotein (LDL) particles.  It is most common to have dyslipidemia in type 2 diabetic patients and it affects 70% of the patients. Diabetis is a major risk factor for atherosclerotic cardiovascular disease (ASCVD) which is one most common reasons  of death in many countries. In this review we have discussed several pharmacological and non paharmacological treatment modalities including several trials which had positive effects on cardiovascular events in patients who has diabetes. ASCVD is is reduced in patients by lowering the LDL-C levels by 30 to 45 % usinf statin therapy. Other therapies like Ezetimibe, pcsk9, has shown posititve effects on loweing LDL-C levels and ASCVD event reduction.

Keywords: Dyslipidemia, lipoprotein, cholesterol, cardiovascular events, triglycerides


How to Cite

DERRIEN, M., & BOUCHET, P. (2021). DYSLIPIDEMIA IN PATIENTS WITH DIABETES: ETIOLOGY AND MANAGEMENT. Asian Journal of Advances in Medical Science, 3(1), 118–126. Retrieved from https://mbimph.com/index.php/AJOAIMS/article/view/2183

Downloads

Download data is not yet available.

References

Fulcher J, et al. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet. 2015;385;1397-1405.

Stone NJ, et al. ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Circulation. 2013; 129 (25, Suppl 2) (2014):S1-S45.

C.P. Cannon et al. Ezetimibe added to statin therapy after acute coronary syndromes. N. Engl. J. Med. 2015;372:2387-2397.

Assmann G, Cullen PH. Schulte Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Münster (PROCAM) study. Circulation. 2002;105:310-315.

Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK, Thompson A, Wood AM, Lewington S, Sattar N, Packard CJ, et al. Emerging risk factors collaboration major lipids, apolipoproteins, and risk of vascular disease. JAMA. 2009;302:1993-2000

Kannel WB, Dawber TR, Friedman GD, Glennon WE, McNamara PM. Risk factors in coronary heart disease. An evaluation of several serum lipids as predictors of coronary heart disease; the framingham study. Ann. Intern. Med. 1964;61:888-899.

Badimon JJ, Badimon L, Fuster V. Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit J. Clin. Invest. 1990;85:1234-1241.

Tangirala RK, Tsukamoto K, Chun SH, Usher D, Puré E, Rader DJ. Regression of atherosclerosis induced by liver-directed gene transfer of apolipoprotein A-I in mice. Circulation. 1999;100:1816-1822.

Kontush A, Lindahl M, Lhomme M, Calabresi L, Chapman MJ, Davidson WS. Structure of HDL: particle subclasses and molecular components Handbook Exp. Pharmacol. 2015;224:3-51.

Farmer EH, Sutton DA. The course of autoxidation reactions in polyisoprenes and allied compounds: V. Observations on fish-oil acids. J Chem Soc. 1943;24:122–125. [Google Scholar]

Halliwell B, Gutteridge JM. Lipid peroxidation in brain homogenates: the role of iron and hydroxyl radicals. J Neurochem. 1997; 69:1330–1331. [PubMed] [Google Scholar]

Goff DC, Gerstein HC, Ginsberg HN, Cushman WC, Margolis KL, Byington RP, Buse JB, Genuth S, Probstfield JL, Simons-Morton DG: Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol. 2007; 99: 4i-20i.

Standards of medical care in diabetes-2009. Diabetes Care. 2009;32(Suppl 1):S13-S61. 10.2337/dc09-S013

Brunzell JD, Davidson M, Furberg CD, Goldberg RB, Howard BV, Stein JH, Witztum JL. Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care. 2008;31:811-822.

Stein EA, Sniderman A, Laskarzewski P: Assessment of reaching goal in patients with combined hyperlipidemia: low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, or apolipoprotein B. Am J Cardiol. 2005;96:36K-43K.

Moon YS, Kashyap ML. Pharmacologic treatment of type 2 diabetic dyslipidemia. Pharmacotherapy. 2004;24:1692-1713. DOI:10.1592/phco.24.17.1692.52340

High-dose atorvastatin therapy achieves 25% reduction in CV events in TNT substudy of diabetic patients. Cardiovasc J S Afr. 2006;17: 206-207.

Ravi Manne, Agilandeswari Devarajan. Development of nicotinic acid controlled release tablets with natural phenolic anti-oxidant polymer by encapsulation technique. Journal of Natural Remedies. 2020;20(4):139-151. [Google Scholar]

Nesto RW. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome. Am J Cardiovasc Drugs. 2005;5:379-387.

Lauring B, Dishy V, Luo WL, Laterza O, Patterson J, Cote J, Chao A, Larson P, Gutierrez M, Wagner JA, Lai E. Laropiprant in combination with extended-release niacin does not alter urine 11-dehydrothromboxane B2, a marker of in vivo platelet function, in healthy, hypercholesterolemic, and diabetic subjects. J Clin Pharmacol. 2009;49:1426-1435.

Shah S, Ceska R, Gil-Extremera B, Paolini JF, Giezek H, Vandormael K, Mao A, McCrary Sisk C, Maccubbin D. Efficacy and safety of extended-release niacin/laropiprant plus statin vs. doubling the dose of statin in patients with primary hypercholesterolaemia or mixed dyslipidaemia. Int J Clin Pract. 2010;64:727-738.

Gleim G, Liu N, Thompson-Bell S. Lipid-altering efficacy and safety profile of co-administered extended release niacin/laropiprant and simvastatin in patients with dyslipidemia [abstract 683]. Circulation. 2007;116:127-10.

Nesto RW. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome. Am J Cardiovasc Drugs. 2005;5:379-387.

Ballantyne CM, Houri J, Notarbartolo A, Melani L, Lipka LJ, Suresh R, Sun S, LeBeaut AP, Sager PT, Veltri EP: Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation. 2003;107:2409-2415.

Colhoun H: After FIELD: should fibrates be used to prevent cardiovascular disease in diabetes?. Lancet. 2005;366:1829-1831.

Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, Drury P, Kesaniemi YA, Sullivan D, Hunt D, Colman P, d'Emden M, Whiting M, Ehnholm C, Laakso M: Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366:1849-1861.

Ginsberg HN, Elam MB, Lovato LC, Crouse JR, Leiter LA, Linz P, Friedewald WT, Buse JB, Gerstein HC, Probstfield J, Grimm RH, Ismail-Beigi F, Bigger JT, Goff DC, Cushman WC, Simons-Morton DG, Byington RP: Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362: 1563-1574.

Moon YS, Kashyap ML: Pharmacologic treatment of type 2 diabetic dyslipidemia. Pharmacotherapy. 2004;24:1692-1713.

Orringer CE, Jacobson TA, Saseen JJ, Brown AS, Gotto AM, Ross JL, Underberg JA. Update on the use of PCSK9 inhibitors in adults: Recommendations from an Expert Panel of the National Lipid Association. J Clin Lipidol. 2017;11:880–890. [PubMed] [Google Scholar]

Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, Stroes ES, Langslet G, Raal FJ, El Shahawy M, Koren MJ, Lepor NE, Lorenzato C, Pordy R, Chaudhari U, Kastelein JJ ODYSSEY LONG TERM Investigators. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372:1489–1499. [PubMed] [Google Scholar]

Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Lecorps G, Mahaffey KW, Moryusef A, Pordy R, Quintero K, Roe MT, Sasiela WJ, Tamby JF, Tricoci P, White HD, Zeiher AM ODYSSEY OUTCOMES Committees and Investigators. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. N Engl J Med. 2018;379:2097–2107. [PubMed] [Google Scholar]

Sabatine MS, Giugliano RP, Wiviott SD, Raal FJ, Blom DJ, Robinson J, Ballantyne CM, Somaratne R, Legg J, Wasserman SM, Scott R, Koren MJ, Stein EA Open-Label Study of Long-Term Evaluation against LDL Cholesterol (OSLER) Investigators. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372:1500–1509. [PubMed] [Google Scholar]

Nicholls SJ, Puri R, Anderson T, Ballantyne CM, Cho L, Kastelein JJ, Koenig W, Somaratne R, Kassahun H, Yang J, Wasserman SM, Scott R, Ungi I, Podolec J, Ophuis AO, Cornel JH, Borgman M, Brennan DM, Nissen SE. Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial. JAMA. 2016;316:2373–2384. [PubMed] [Google Scholar]

Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR FOURIER Steering Committee and Investigators. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017;376:1713–1722. [PubMed] [Google Scholar]

Sabatine MS, Leiter LA, Wiviott SD, Giugliano RP, Deedwania P, De Ferrari GM, Murphy SA, Kuder JF, Gouni-Berthold I, Lewis BS, Handelsman Y, Pineda AL, Honarpour N, Keech AC, Sever PS, Pedersen TR. Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. Lancet Diabetes Endocrinol. 2017;5:941–950. [PubMed] [Google Scholar]

https://www.grandviewresearch.com/industry-analysis/hyperlipidemia-drugs-market

Hlatky MA, Kazi DS. PCSK9 Inhibitors: Economics and Policy. J Am Coll Cardiol. 2017;70:2677–2687. [PubMed] [Google Scholar]

The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA. 1984;251:351–364. [PubMed] [Google Scholar]

Jialal I, Abby SL, Misir S, Nagendran S. Concomitant reduction in low-density lipoprotein cholesterol and glycated hemoglobin with colesevelam hydrochloride in patients with type 2 diabetes: a pooled analysis. Metab Syndr Relat Disord. 2009;7:255–258. [PMC free article] [PubMed] [Google Scholar]

Oikawa S, Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, Sasaki J, Hishida H, Itakura H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K JELIS Investigators, Japan. Suppressive effect of EPA on the incidence of coronary events in hypercholesterolemia with impaired glucose metabolism: Sub-analysis of the Japan EPA Lipid Intervention Study (JELIS) Atherosclerosis. 2009;206:535–539. [PubMed] [Google Scholar]

ORIGIN Trial Investigators. Bosch J, Gerstein HC, Dagenais GR, Díaz R, Dyal L, Jung H, Maggiono AP, Probstfield J, Ramachandran A, Riddle MC, Rydén LE, Yusuf S. n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med. 2012;367:309–318. [PubMed] [Google Scholar]

Deeg MA, Buse JB, Goldberg RB, Kendall DM, Zagar AJ, Jacober SJ, Khan MA, Perez AT, Tan MH: Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia. Diabetes Care. 2007;30:2458-2464

Berhanu P, Kipnes MS, Khan MA, Perez AT, Kupfer SF, Spanheimer RC, Demissie S, Fleck PR: Effects of pioglitazone on lipid and lipoprotein profiles in patients with type 2 diabetes and dyslipidaemia after treatment conversion from rosiglitazone while continuing stable statin therapy. Diab Vasc Dis Res. 2006; 3:39-44.

Reaven GM, Lardinois CK, Greenfield MS, Schwartz HC, Vreman HJ: Effect of acarbose on carbohydrate and lipid metabolism in NIDDM patients poorly controlled by sulfonylureas. Diabetes Care. 1990;13 (Suppl 3):32-36.

Hariyanto TI, Kurniawan A. Dyslipidemia is associated with severe coronavirus disease 2019 (COVID-19) infection. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2020;14(5):1463-1465.

Hedayatnia M, Asadi Z, Zare-Feyzabadi R, Yaghooti-Khorasani M, Ghazizadeh H, Ghaffarian-Zirak R, Ghayour-Mobarhan M. Dyslipidemia and cardiovascular disease risk among the MASHAD study population. Lipids in Health and Disease. 2020;19(1):1-11.